FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 4707 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study. PMID 36720560 · RMD Open · 2023-Jan The record is a Phase III randomized trial of a drug (tofacitinib) but does not meet the core oncology or time-to-event endpoint criteria required for this adjudication cohort. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. PMID 36609807 · J Neurooncol · 2023-Jan This is a safety-focused analysis of hematotoxicity from a Phase III RCT, not an efficacy report with a primary time-to-event endpoint. Therefore, it does not meet the inclusion criteria for an efficacy-focused Kaplan-Meier digitization cohort. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A series of two-sample non-parametric tests for quantile residual life time. PMID 36593432 · Lifetime Data Anal · 2023-Jan The article is a statistical methodology paper proposing new tests for quantile residual lifetime and applies them to a Phase III trial, but it is not an original clinical trial result report. It does not explicitly describe a drug intervention as the primary focus, and the main purpose is to introduce statistical methods rather than report trial efficacy. Therefore, it does not meet eligibility criteria for a drug intervention report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. PMID 36534262 · Int J Clin Oncol · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 2 Panel · risk visible |
| The Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder Cancer. PMID 36517193 · Semin Radiat Oncol · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. PMID 36493792 · Lancet Oncol · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 1 Figure · 3 Panel · risk visible |
| Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial. PMID 36471691 · EClinicalMedicine · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada. PMID 36463730 · Lung Cancer · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. PMID 36460017 · Lancet Oncol · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT). PMID 36459768 · Eur J Cancer · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02). PMID 36434888 · Eur J Cancer · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS). PMID 36414827 · Int J Clin Oncol · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. PMID 36403580 · Lancet Neurol · 2023-Jan 未发现恶性肿瘤人群证据。 |
H
S
B
|
严格 v3 独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS. PMID 36402700 · Clin Lymphoma Myeloma Leuk · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study. PMID 36379880 · Clin Lymphoma Myeloma Leuk · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
S
B
|
严格 v3 独有 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. PMID 36379186 · Eur J Cancer · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 5 Panel · risk visible |
| Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. PMID 36341767 · J Hepatol · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). PMID 36328033 · Lancet Gastroenterol Hepatol · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. PMID 36252599 · Lancet Respir Med · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. PMID 36240972 · J Thorac Oncol · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study). PMID 36220461 · Ann Oncol · 2023-Jan The record is an original RCT in oncology, but it is not eligible for the cohort because it does not report results for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The study's stated primary aim involves local recurrence, but that outcome is not reported in this abstract; the results presented are limited to short-term morbidity and pathology. The intervention includes chemoradiotherapy (CRT) but the analysis is not of a drug-specific efficacy endpoint, and CRT is part of a combined modality (CRT + local excision). |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. PMID 36216658 · Eur Urol · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial. PMID 36184068 · J Thorac Oncol · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2. PMID 36168844 · Cancer Sci · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Impact of Early Dorsal Venous Complex Ligation on Urinary Continence Recovery after Robot-assisted Radical Prostatectomy: Results from a Phase 3 Randomized Controlled Trial. PMID 36154808 · Eur Urol Focus · 2023-Jan The record is a Phase III randomized trial in human prostate cancer (oncology) with a time-to-event primary endpoint (biochemical recurrence-free survival). It reports original results. However, the intervention is a surgical technique (early vs standard dorsal venous complex ligation) and does not involve a drug-containing intervention. The eligibility criteria require a drug-containing intervention. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. PMID 36066725 · Gastric Cancer · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 1 Figure · 1 Panel · risk visible |
| PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. PMID 35907001 · Eur Arch Otorhinolaryngol · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). PMID 35900311 · J Hepatobiliary Pancreat Sci · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 2 Figure · 2 Panel · risk visible |
| CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study. PMID 35848358 · Cancer Med · 2023-Jan 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 2 Figure · 5 Panel · risk visible |
| Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature. PMID 36915455 · J Gastrointest Oncol · 2023-Feb-28 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 5 Panel · risk visible |
| Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. PMID 36541957 · Blood Adv · 2023-Feb-28 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 3 Figure · 3 Panel · risk visible |
| Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. PMID 36849516 · Nat Commun · 2023-Feb-27 The report is an analysis of acquired resistance mechanisms from a Phase 3 randomized trial but does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR results. It focuses on genomic/biomarker analysis of progression samples. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review. PMID 36979659 · Biomedicines · 2023-Feb-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Rucaparib or Physician's Choice in Metastatic Prostate Cancer. PMID 36795891 · N Engl J Med · 2023-Feb-23 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). PMID 36814222 · BMC Cancer · 2023-Feb-22 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. PMID 36327426 · J Clin Oncol · 2023-Feb-20 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | confirmed 3 Figure · 10 Panel · risk visible |
| Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. PMID 36791159 · N Engl J Med · 2023-Feb-16 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. PMID 36426410 · Cancer · 2023-Feb-15 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis. PMID 36121651 · Int J Cancer · 2023-Feb-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Implications of recent neoadjuvant clinical trials on the future practice of radiotherapy in locally advanced rectal cancer. PMID 36844136 · World J Gastroenterol · 2023-Feb-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. PMID 35849035 · Neuro Oncol · 2023-Feb-14 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. PMID 36765311 · BMC Cancer · 2023-Feb-10 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 4 Panel · risk visible |
| Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. PMID 36395435 · J Clin Oncol · 2023-Feb-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 2 Figure · 7 Panel · risk visible |
| Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. PMID 36780674 · N Engl J Med · 2023-Feb-09 The study is a Phase III randomized trial with primary time-to-event efficacy endpoints (DFS, OS) for a human malignancy and reports original results. However, it is ineligible because it does not involve a drug-containing intervention; it compares surgical techniques (sublobar vs. lobar resection). |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. PMID 36130300 · Blood · 2023-Feb-09 While the record describes a Phase III randomized trial with a drug intervention (ixazomib) and a time-to-event endpoint (PFS), it is a secondary/post-hoc analysis of MRD dynamics and prognostication, not the original primary efficacy result report of the trial. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial. PMID 36798177 · Res Sq · 2023-Feb-08 The study is a prognostic/biomarker analysis from a Phase 3 trial and does not report a primary/key secondary time-to-event efficacy endpoint as required for eligibility. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform. PMID 36750848 · Radiat Oncol · 2023-Feb-07 The study is a randomized Phase III trial in oncology with time-to-event efficacy endpoints (OS, DFS), but it does not involve a drug-containing intervention. The intervention is a comparison of two radiation therapy platforms (Gamma Knife vs. linac-based radiosurgery). The criteria require a drug-containing intervention, which is not present. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. PMID 36746459 · BMJ · 2023-Feb-06 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study. PMID 36717163 · Int J Gynecol Cancer · 2023-Feb-06 The record is a protocol for an ongoing phase III randomized trial with a primary time-to-event endpoint (DFS). It is not a result report. Furthermore, the intervention arms (chemoradiation with tailored field vs. surgical staging with tailored chemoradiation) do not explicitly mention a specific drug agent, making the drug intervention criterion uncertain. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. PMID 36739285 · NPJ Breast Cancer · 2023-Feb-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |